September 30, 2020

BDR Pharma to launch 400mg Favipiravir tablets for treating coronavirus sufferers in India



New Delhi: Drug agency BDR Prescription drugs on Friday mentioned it plans to launch 400 mg Favipiravir tablets, used for treating COVID-19 sufferers, within the nation. The ‘BDFAVI‘ 400 mg tablets will likely be priced at Rs 990 for a strip of 10 tablets, BDR Pharma mentioned in an announcement. Every pill will value Rs 99.

In August, the corporate launched 200 mg Favipiravir tablets.

“We purpose to make BDFAVI obtainable in enough portions to fulfill the excessive demand for the drug within the Indian market to assist curb the present disaster… introducing the next dosage is an try to make sure a smoother expertise to sufferers and caregivers,” BDR Pharma CMD Dharmesh Shah mentioned.

The corporate had obtained approval from the Medication Controller Basic of India (DCGI) to fabricate Favipiravir to deal with sufferers with gentle to average COVID-19 signs underneath the model identify BDFAVI, in keeping with the assertion.